Insulet Initiated At Buy, Revenues Expected To Double

Jefferies & Company has published a research report on Insulet Corporation PODD and has initiated coverage on the company with a Buy rating. In the report, Jefferies writes "With adoption of the OmniPod still low and next generation products on tap for 2011, Insulet is poised for substantial growth. Revenue is expected to double over the next two years." Jefferies has also issued a $19 price target on Insulet Corporation, which closed yesterday at $13.73.